Printer Friendly

Avoid beta-lactams in adults, children with STEC 0157.


SAN FRANCISCO -- Treatment of Shiga toxin-producing Escherichia coli 0157 infection with beta-lactams is associated with increased risk for post-diarrheal hemolytic uremic syndrome in both children and adults, according to findings from a population-based study.

Beta-lactam antibiotics are particularly troublesome in this setting, the findings suggest.

Among 1,308 patients with the infection, known as STEC 0157--the leading cause of postdiarrheal hemolytic uremic syndrome (HUS) in the United States--137 had HUS, and 44 had partial HUS, Dr. Melissa Tobin-D'Angelo reported at an annual scientific meeting on infectious diseases.

Up to 15% of patients with STEC 0157 diarrhea develop HUS, which comprises microangiopathic hemolytic anemia, acute azotemia, and thrombocytopenia, said Dr. Tobin-D'Angelo of the Georgia Department of Public Health, Atlanta.

Generally in this observational study, antibiotic treatment was used more commonly and HUS occurred less frequently with increasing age quartile. Among those under age 5 years, 12% received antibiotics and 22% had HUS; among those aged 514 years, 11% received antibiotics and 11% had HUS; among those aged 1539 years, 45% received antibiotics and 5% had HUS; and among those aged 40 years or older, 52% received antibiotics and 4% had HUS.

Adults aged 40 and older were more likely than were those in all other age groups to receive beta-lactam antibiotics (8% vs. 4%) or metronidazole (31% vs. 11%), while children under age 15 years were more likely than were others to receive sulfonamides (5% vs. 1%), Dr. Tobin-D'Angelo reported at the conference, the combined annual meetings of the Infectious Diseases Society of America, the Society for Healthcare Epidemiology of America, the HIV Medicine Association, and the Pediatric Infectious Diseases Society.

No overall association was seen between antibiotic treatment and HUS, but among children aged 5-14 years, treatment with any antibiotic and treatment with metronidazole were significantly associated with HUS (odds ratios, 2.6 and 4.0, respectively). Also, among all subjects, beta-lactam antibiotics and sulfonamides were associated with at least partial HUS (odds ratios, 2.9 and 2.2, respectively), she noted.

Study subjects were patients with STEC 0157 identified through active, population-based surveillance in 10 states during 2006-2010. Patients or caregivers were interviewed, and data were extracted from medical records. Only antibiotic exposures during the first 7 days of illness or before HUS onset were included in the analysis.

"Controversy remains regarding antibiotic treatment of STEC 0157 and its possible association with an increased risk of HUS; antibiotics increase Shiga toxin production and release in vitro, but this varies by antibiotic class and dose, and it has varied by study," Dr. Tobin-D'Angelo said.

"We recommend that beta-lactams should not be prescribed to any patient of any age with known STEC 0157 infection and that clinicians should consider the risk of HUS when prescribing beta-lactams to any patients with diarrhea that could be caused by STEC 0157," she said.

It is also prudent to avoid the use of other antibiotics for the treatment of STEC 0157 diarrhea because of evidence of increased HUS risk from other studies, and because of the lack of data demonstrating any therapeutic benefit, she added.


Major finding: Beta-lactam antibiotics were associated with at least partial HUS {odds ratio, 2.9),

Data source: A prospective cohort study of 1,308 patients.

Disclosures: Dr. Tobin-D'Angelo reported having no disclosures.
COPYRIGHT 2013 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Worcester, Sharon
Publication:Pediatric News
Date:Nov 1, 2013
Previous Article:Maternal smoking linked to myriad infant infections.
Next Article:ID consult: improving diagnosis of otitis media.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters